PASTINA, PIERPAOLO
 Distribuzione geografica
Continente #
NA - Nord America 1.915
EU - Europa 1.517
AS - Asia 267
OC - Oceania 4
AF - Africa 1
SA - Sud America 1
Totale 3.705
Nazione #
US - Stati Uniti d'America 1.911
GB - Regno Unito 612
IE - Irlanda 334
CN - Cina 178
IT - Italia 144
UA - Ucraina 128
SE - Svezia 112
FR - Francia 62
DE - Germania 37
FI - Finlandia 31
VN - Vietnam 30
TR - Turchia 27
ES - Italia 23
IN - India 18
BE - Belgio 16
RU - Federazione Russa 13
IR - Iran 7
AU - Australia 4
CA - Canada 4
SG - Singapore 4
AT - Austria 2
BD - Bangladesh 2
AM - Armenia 1
CL - Cile 1
LT - Lituania 1
NL - Olanda 1
PL - Polonia 1
ZA - Sudafrica 1
Totale 3.705
Città #
Southend 565
Dublin 324
Fairfield 288
Chandler 169
Ashburn 156
Woodbridge 136
Ann Arbor 125
Wilmington 112
Seattle 110
Houston 105
Menlo Park 104
Jacksonville 103
Cambridge 85
Siena 56
New York 50
Beijing 43
Princeton 43
Fremont 40
Dong Ket 30
Nanjing 28
Dearborn 27
Izmir 27
Málaga 23
Helsinki 20
Shanghai 20
Boardman 17
Brussels 16
San Diego 15
San Mateo 14
Florence 12
Shenyang 12
Moscow 11
Hebei 9
Tianjin 8
Nanchang 7
Ningbo 7
Jiaxing 6
Lancaster 6
Zanjan 6
Fort Worth 5
Phoenix 5
Changsha 4
Hangzhou 4
Hounslow 4
Kunming 4
Reggio Calabria 4
Renton 4
Fuzhou 3
Guangzhou 3
Jinan 3
Sacramento 3
San Vitaliano 3
Taizhou 3
Zhengzhou 3
Bologna 2
Changchun 2
Dhaka 2
Falkenstein 2
Henderson 2
Kilburn 2
Lanzhou 2
Leinì 2
London 2
Los Angeles 2
Priocca 2
Redwood City 2
Sezze 2
Toronto 2
Vienna 2
Wuhan 2
Alghero 1
Atlanta 1
Auburn Hills 1
Bagnoli del Trigno 1
Bangalore 1
Borghetto Lodigiano 1
Brainerd 1
Campi Bisenzio 1
Canberra 1
Caserta 1
Cessaniti 1
Chaoyang 1
College Station 1
Crotone 1
Delhi 1
Edinburgh 1
Gauteng 1
Giussano 1
Islington 1
Katy 1
Kyiv 1
Melbourne 1
Milan 1
Modena 1
Montespertoli 1
Montreal 1
Nagold 1
New Bedfont 1
Norwalk 1
Philadelphia 1
Totale 3.052
Nome #
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 239
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 230
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. 218
3D bone texture analysis as a potential predictor of radiationinduced insufficiency fractures 198
Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of response to radiosurgery (SRS) 191
Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT 179
Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab 173
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 166
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients 162
Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy 153
Epidermal Growth Factor Receptor Expression predicts Time and Patterns of Recurrence in Glioblastoma Patients Following Radiotherapy and Temozolomide. 151
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). 146
The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer 145
null 139
null 130
null 126
Inflammatory status and lymphocyte of infiltration of primary tumor predict survival of prostate cancer patients undergone prostate radical radiotherapy 126
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 124
null 117
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. 116
null 92
null 82
CDK4, CDK6/cyclin‐d1 complex inhibition and radiotherapy for cancer control: a role for autophagy 58
Combined epidermal growth factor receptor and beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma 48
Bone texture analysis using CT-simulation scans to individuate risk parameters for radiation-induced insufficiency fractures. 46
Prognostic Value of MR Imaging Texture Analysis in Brain Non-Small Cell Lung Cancer Oligo-Metastases Undergoing Stereotactic Irradiation. 43
The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma. 40
In Regard to Kubicek et al. 38
Immunotherapy of colorectal cancer: new perspectives after a long path. 31
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab 27
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 25
Magnetic-resonance-imaging texture analysis predicts early progression in rectal cancer patients undergoing neoadjuvant chemoradiation 22
Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival? 14
Totale 3.795
Categoria #
all - tutte 10.429
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.429


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020846 93 25 55 111 56 81 81 106 92 67 37 42
2020/2021624 25 76 10 56 45 83 16 82 49 87 19 76
2021/2022388 25 38 38 18 25 18 20 29 29 38 39 71
2022/2023533 26 60 77 80 50 86 11 40 51 31 9 12
2023/2024539 9 6 63 23 15 150 240 0 2 12 2 17
Totale 3.795